September 24, 2013

The global market for Type 2 diabetes will nearly double over the next six years, according to a new report.

April 19, 2013

The Food and Drug Administration has given tentative approval to two generic diabetes drugs made by Sun Pharmaceutical Industries, the Indian drug maker said.

October 3, 2012

A drug marketed by Boehringer Ingelheim Pharmaceuticals and Eli Lilly reduced blood sugar in elderly patients with Type 2 diabetes and in adults with diabetic nephropathy, according to results of three studies presented at a diabetes meeting in Berlin.

September 14, 2012

Drug makers Boehringer Ingelheim and Eli Lilly have created a new online educational program for people with Type 2 diabetes.

June 20, 2011

Last month, the Food and Drug Administration approved Tradjenta (linagliptin), an oral Type 2 diabetes drug made by German drug maker Boehringer Ingelheim and Indianapolis-based Eli Lilly. The drug belongs to the class known as dipeptidyl peptidase-4 inhibitors, which also includes Merck’s Januvia (sitagliptin). With diabetes affecting some 26 million Americans and growing rapidly, Drug Store News spoke with Wa’el Hashad, BI’s VP cardiovascular and metabolic disorders marketing, about what the approval of Tradjenta means for the diabetes market.


March 15, 2011

While several drugs to treat Type 2 diabetes are on the market, researchers have found that the best first-line option is metformin.

January 7, 2011

A new oral treatment for Type 2 diabetes hit the shelves Friday.

December 7, 2010

Supplier News — Fera Pharmaceuticals has recently launched two new topical ointments. The New York-based company has developed Ilotycin (erythromycin) and Garamycin (gentamicin) ophthalmic ointments, both for the treatment of bacterial infections of the eye. “Our goal is simple: to keep more quality healthcare choices alive for the people who need them,” company co-founder Frank DellaFera said.